Hepatitis B and C seroprevalence in patients with diabetes mellitus and its relationship with microvascular complications

Abstract

IntroductionDiabetic patients are susceptible to bacterial, viral and fungal infections because of various deficiencies in the immune system.AimTo investigate a possible link between hepatitis B/C prevalence and microvascular complications as well as duration of diabetes.Material and methodsIn total 1263 diabetic patients (1149 type 2, 114 type 1) were enrolled in the study. The control group consisted of 1482 healthy blood donors who were over 40 years old. All diabetic patients were tested for HBsAg, anti-HBs and anti-HCV beside routine laboratory tests. Diabetic patients were divided into three groups according to their diabetes duration, and all of the patients were scanned for microvascular complications. Demographic data of all patients were recorded.ResultsHBsAg seropositivity was 3.7% in diabetic patients and 1.08% in the control group; this difference was statistically significant (p < 0.001). HBsAg positivity rates in type 1 and type 2 diabetics were 0.8% and 4%, respectively (p = 0.09). HCV seropositivity was 2.2% for diabetics and 0.5% for the control group; this difference was statistically significant (p < 0.001). Anti-HCV seropositivity in type 1 and type 2 diabetics was 1.75% and 2.26%, respectively. There was no relationship between diabetes duration and hepatitis B-C prevalence (p > 0.05). Also, no relationship was found between microvascular complications of diabetes and hepatitis B/C seropositivity.ConclusionsHepatitis B and C seroprevalence was found to be increased in diabetes mellitus; however, there was no relationship between hepatitis seroprevalence and the duration or microvascular complications of diabetes.

Non-autoimmune diabetes mellitus and the risk of virus infections: a systematic review and meta-analysis of case-control and cohort studies

“…A total of 11 viruses were reported: HCV (43 studies) 10 , 24 – 60 , 82 , 84 , 86 , 88 , 89 , HBV (27 studies) 10 , 30 , 35 , 36 , 38 , 41 , 44 , 48 , 52 , 53 , 56 , 59 , 60 , 66 – 74 , 82 , 84 , 85 , HHV8 (8 studies) 12 , 61 – 65 , 81 , CMV (5 studies) 76 – 80 , SARS-CoV-2 (1 study) 83 , H1N1 virus (1 study) 87 , HSV1 (1 study) 75 , TTV (1 study) 37 , Parvovirus B19 (1 study) 79 , coxsackie B (1 study) 79 and HGV (1 study) 37 (Table 1 ).…”

Seroprevalence of hepatitis B and C virus infections among diabetic patients in Kisangani (North-eastern Democratic Republic of Congo)

“…Most studies have not observed a difference in seroprevalence of HBV between diabetic and non-diabetic subjects [7, 10, 20, 21]. Only a few studies indicate a higher risk of HBV infection in diabetics compared to non-diabetics [6, 22, 23], and a high risk of diabetes mellitus in HBV infected patients [24].…”

“…Regarding the seroprevalence of these viruses in diabetics, the results remain conflicting. Some studies have reported high seroprevalence of HBV and HCV among diabetics [2, 6-8] while others have not observed a significant difference compared to control groups [9-11]. In Kisangani, a city in the north-eastern of the Democratic Republic of Congo, diabetes mellitus is a growing disease [12, 13].…”

The Prevalence and Risk Factors of Type II Diabetes Mellitus Among Patients with Hepatitis B Virus: A Descriptive Correlational Study

“…Another study on 400 patients with a definite diagnosis of DM indicated that 2.5% suffered from HCV infection, while the prevalence of HCVAb positivity in the nondiabetic population was 1% (12). In 3 other studies, the prevalence of DM among patients with hepatitis was estimated at 14.3% (13), 2.2% (14), and 39% (15), respectively.…”